Perinatal probiotic intervention prevented allergic disease in a Caesarean‐delivered subgroup at 13‐year follow‐up

Summary Background The long‐term effects of probiotic intervention for primary prevention of allergic diseases are not well known. We previously reported less eczema until 10 years in our probiotic intervention trial. Objective To investigate the effect of early probiotic intervention on the prevale...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental allergy 2019-04, Vol.49 (4), p.506-515
Main Authors: Kallio, Sampo, Kukkonen, Anna Kaarina, Savilahti, Erkki, Kuitunen, Mikael
Format: Article
Language:English
Subjects:
Allergic diseases
Allergies
Blood
Disease
Eczema
Gestation
Histamine
Hypersensitivity
Immunoglobulin E
Infants
Long-term effects
Probiotics
Questionnaires
Skin diseases
Statistical analysis
Wheezing
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Background The long‐term effects of probiotic intervention for primary prevention of allergic diseases are not well known. We previously reported less eczema until 10 years in our probiotic intervention trial. Objective To investigate the effect of early probiotic intervention on the prevalence of allergic diseases up to 13 years of age. Methods Pregnant women (n = 1223) carrying a child at a high risk of allergy (at least one parent with allergic disease) were randomized to receive a mixture of probiotics (Lactobacillus rhamnosusGG and LC705, Bifidobacterium breve Bb99 and Propionibacterium freudenreichii) or placebo in a double‐blind manner from 36 weeks of gestation until birth. Their infants received the same product for the first six months (registration number NCT00298337). At 13‐year follow‐up, the participants were requested to return a questionnaire and to provide a blood sample. Results A questionnaire was returned by 642 participants (63.1% of intention‐to‐treat infants), and 459 provided a blood sample. In the whole cohort, there were no statistically significant differences in doctor‐diagnosed allergic disease (55.2% and 59.0%, probiotic and placebo group, respectively) or allergic disease (47.9% and 51.6%) based on the ISAAC questionnaire data. Inhalant‐specific IgE sensitization (>0.7 kU/L) was 59.3% in the probiotic group and 49.8% in the placebo group (P = 0.040). In a post hoc analysis made in Caesarean‐delivered subgroup, allergy was reported in 41.5% of the probiotic group and 67.9% of the placebo group (P = 0.006), and eczema in 18.9% and 37.5%, respectively (P = 0.031). In the whole cohort, 8.5% of the probiotic group had suffered from wheezing attacks during the previous 12 months vs 14.7% in the placebo group (P = 0.013). There were no statistically significant differences discovered between the characteristics of the participating group and the dropout group. Conclusions Probiotic intervention protected Caesarean‐delivered subgroup from allergic disease and eczema, but not the total cohort.
ISSN:0954-7894
1365-2222
DOI:10.1111/cea.13321